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INTRODUCTION
According to the Causes of Death Statistics of Korea, published 
in 2016, deaths related to cancer accounted for 27.8% of the to-
tal mortality rate, which was the highest among the 10 leading 
causes of death. The number of cancer cases and deaths has 
been steadily increasing every year, with the cancer death rate 
increasing by 1.4% in the previous year.1 Pancreatobiliary can-
cer is one of the 10 most common cancers in Korea, account-
ing for 2.7% of all cancer cases in 2014. In contrast to the im-
proving survival rates for major cancers, including stomach and 
breast cancers, the survival rate for pancreatobiliary cancer has 
shown minimal increases, and the 5-year survival rate remains 
less than 10%.2
Pancreatobiliary cancer shows poor prognosis, and many 
patients experience difficulty having a positive outlook toward 
treatment, which subsequently leads to serious psychological 
distress. Studies examining the prevalence of depression in can-
cer patients have shown that pancreatobiliary cancer is most 
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highly associated with depression (33–50%), followed by oro-
pharyngeal cancer (22–57%), lung cancer (11–44%), and breast 
cancer (1.4–46%), with the subjective quality of life (QoL) of 
the patients with pancreatobiliary cancer being the lowest.3,4 
Due to such psychological distress, many patients with pan-
creatobiliary cancer experience anxiety and depression after 
being diagnosed, and develop a negative outlook on life. These 
patients are also less willing to undergo treatment and fre-
quently discontinue curative treatment.5 Thus, a multidisci-
plinary approach that includes psychiatric care in addition to 
cancer therapy is essential for the treatment of patients with 
pancreatobiliary cancer.
In recent years, a number of studies have focused on the psy-
chological aspects of patients with advanced cancer and have 
reported the importance of a patient’s sense of meaning in life 
and spiritual well-being. Accordingly, the need for psycholog-
ical care through psychiatric intervention is being increasingly 
acknowledged.6,7 Due to serious psychological distress, patients 
with advanced cancer experience a number of psychological 
symptoms, including depression, anxiety, insomnia, anhedo-
nia, and personal devaluation, and some patients even experi-
ence a loss of meaning of life and a desire for hastened death.8,9 
One of the psychotherapeutic interventions for patients with 
advanced cancer is meaning-centered psychotherapy (MCP). 
It was first conceptualized by Viktor E. Frankl and has been 
further developed by a number of other researchers for use in 
individual or group psychotherapy;10,11 MCP has been shown 
to help patients increase a sense of meaning in one’s life dur-
ing distressing conditions and provide hope to patients with 
cancer even if they are not cured. Studies have shown that MCP 
is effective in enhancing QoL and spiritual well-being, as well 
as reducing depression and desire for death in patients with 
advanced cancer.12,13 The present study aimed to investigate the 
effectiveness of MCP for patients with pancreatobiliary cancer 
who reported clinically significant psychological distress. 
MATERIALS AND METHODS
Recruitment of study participants and ethics approval
A total of 37 patients with pancreatobiliary cancer were recruit-
ed from outpatient clinics at three university general hospitals 
from December 2015 to October 2017: Gangnam Severance 
Hospital, Yonsei University College of Medicine; Yeungnam 
University College of Medicine; and Konyang University Col-
lege of Medicine. The recruited patients (aged ≥20 years) were 
scheduled to undergo surgery or receive treatment after being 
diagnosed with pancreatobiliary cancer. The patients did not 
exhibit cognitive impairment, understood the purpose of the 
study, and provided consent to participate in the study. For 
initial assessment, self-report questionnaires were adminis-
tered to the patients by registered nurses at each of the three 
hospitals. Based on the initial assessment, patients who met 
one of the following criteria were recommended to participate 
in MCP: 1) a score of 8 or higher on both the anxiety and de-
pression subscales of the Hospital Anxiety and Depression 
Scale (HADS), 2) a score of 4 or more on the distress thermom-
eter, or 3) a score of 18 or more in the helpless-hopeless sub-
scale of the Mini-Mental Adjustment to Cancer Scale (MAC). 
MCP was provided to the patients who met the above criteria 
and wished to participate in this study. Patients who refused to 
participate in MCP or did not meet the inclusion criteria for 
MCP group were assigned to the non-MCP group. The ques-
tionnaires were administered again 2 months after completing 
MCP during a follow-up evaluation of the patients’ psycho-
logical characteristics. Demographic data of the patients were 
collected during the initial assessment, and electronic medi-
cal records were used to examine the patients’ medical data, in-
cluding pancreatobiliary cancer stages. This study was reviewed 
and approved by the Institutional Review Boards of the Gang-
nam Severance Hospital (Approval No. 3-2015-0269) including 
all participating institutions.
Meaning-centered psychotherapy 
A psychiatrist or a clinical psychologist who had received 
training in MCP conducted the MCP sessions. The patients in 
the present study received MCP individually because sched-
uling for a group intervention was often difficult due to the 
patients’ health conditions and cancer therapy schedules. All 
patients underwent surgery before the start of MCP and re-
ceived MCP during chemotherapy, except for one patient who 
had not received any other treatment after surgery. Most pa-
tients received MCP on the day of their outpatient visit, and 
each patient participated in four sessions of MCP. The content 
of the sessions was divided into stress management and MCP. 
The sessions addressed the topics of accepting cancer and stress 
management, reviewing the concept of meaning of life and re-
discovering it despite the limitations related to cancer (Table 
1). Each session lasted approximately 1 hour. At the end of 
each session, the patients were provided related reading ma-
terial or homework and were instructed to read or try them 
before the next session.
Assessment scales
The following assessment scales were used in the study: the 
HADS, for the assessment of depression and anxiety;14 the 
MAC, for the assessment of psychological and behavioral re-
sponses to cancer;15 the European Organization for Research 
and Treatment of Cancer (EORTC) quality of life questionnaire 
core 30 (QLQ-C30), for the assessment of global quality of life; 
the EORTC pancreatic cancer-specific module (QLQ-PAN26), 
for the assessment of QoL specific to patients with pancreato-
biliary cancer;16,17 and Social Readjustment Rating Scale 
(SRRS), for the quantification of psychosocial adjustments to as-
sess personal stress levels from various stressors.18 The National 
Comprehensive Cancer Network distress thermometer (DS-
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DT) was included in the initial assessment to evaluate the pa-
tients’ gross distress levels.19 The MAC used in this study is a 
minimized version of the widely used Mental Adjustment to 
Cancer scale. It contains 29 items using a four-point Likert 
scale, which includes the following five adjustment styles: 
fighting spirit (FS), helpless-hopeless (HH), anxious preoccu-
pation (AP), fatalism (FA), and cognitive avoidance (CA). Ac-
cording to previous studies on standardization of the Korean 
version of MAC, FA and FS are associated with positive atti-
tudes, while others are associated with negative attitudes. The 
QLQ-C30 and QLQ-PAN26 comprise 30 and 26 items, respec-
tively. In the present study, the functional scales [physical func-
tion (PF), role function (RF), cognitive function (CF), emotional 
function (EF), social function (SF)] and QoL scale were assessed 
using the QLQ-C30. Symptom scales (pancreatic pain, diges-
tive, altered bowel habit, body image, satisfaction with health 
care, and sexual functioning) were assessed using the QLQ-
PAN26. The QoL scale employs a seven-point linear scale, with 
scores ranging from 1 to 7, and the other items are evaluated on 
a four-point Likert scale. The raw scores for each item were 
transformed to scores ranging from 0 to 100 according to the 
EORTC Scoring guidebook.20 Higher scores in the functional 
scales and QoL scale indicate better QoL, while lower scores 
in the symptoms scales indicate better QoL.
Statistical analysis 
The sociodemographic characteristics and questionnaire 
scores for psychiatric assessment of the MCP and non-MCP 
groups were analyzed. The Kolmogorov-Smirnov test was used 
to test for normality, and Fisher’s exact test and Mann-Whitney 
U test were used to assess homogeneity between the groups. 
Paired t-test and Wilcoxon signed rank test were used to com-
pare the questionnaire scores at the initial and follow-up as-
sessments of the MCP and non-MCP groups. Changes in scores 
were analyzed using independent t-test and Mann-Whitney 
test. Analysis of covariance (ANCOVA) was conducted to sta-
tistically control for differences in initial assessment scores be-
tween the MCP and non-MCP groups for more accurate anal-
ysis. All statistical tests were two-tailed, and p values less than 
0.05 were considered statistically significant. All data were an-
alyzed using SPSS ver. 22.0 (IBM Corp., Armonk, NY, USA).
RESULTS
General characteristics and initial assessments
Of the 37 patients who completed the initial assessment, 24 re-
ceived MCP (Table 2). The mean ages of the MCP (63.13±10.28 
years) and non-MCP (67.08±10.93 years) groups were not sig-
nificantly different (p=0.287). In the MCP group, 15 (62.5%) 
patients were men and nine (37.5%) were women. The pro-
portion of married individuals was high (79.2%). The mean 
Table 1. Weekly Topics and Goals of MCP
Session Topics Goals
Stress management
1 Acceptance of cancer
Stress management
1) Preparing to accept cancer
2) Observing and managing stress
3) Writing an activity list that provides comfort and joy
4) Finding one’s resources 
2 Learning coping skills 
Anger management
1) Understanding one’s coping style
2) Learning other coping strategies
3) Observing and managing anger 
MCP
3 Concepts and sources of meaning 
Cancer and meaning
1) Introduction and overview 
2) Identity before and after cancer diagnosis 
3) Life as a living legacy (past, present, and future)
4 Attitudinal, creative, and experiential sources of meaning 
Reflections and hopes for the future
1) Encountering life’s limitations 
2) Engaging in life via creativity and responsibility
3)  Review the sources of meaning, discussion of hopes for the future 
MCP, meaning-centered psychotherapy.
Table 2. Patient Demographic Data
Variable MCP (n=24) Non-MCP (n=13) p value
Age (yr) 63.13±10.28 67.08±10.93 0.287
Gender 0.850
Male 15 (62.5) 8 (61.5)
Female 9 (37.5) 5 (38.5)
Marital status 0.558
Married 19 (79.2) 11 (84.6)
Unmarried 0 (0.0) 0 (0.0)
Divorced 2 (8.3) 0 (0.0)
Widowed 3 (12.5) 2 (15.4)
Education (yr) 9.39±4.52 10.08±5.07 0.678
TNM stage 0.140
I 6 (25.0) 5 (38.5)
II 15 (62.5) 5 (38.5)
III 1 (4.2) 2 (15.4)
IV 2 (8.3) 1 (7.7)
Time from the cancer diagnosis  
  to the initial assessment (day)
30.36±68.53 53.36±69.91 0.374
MCP, meaning-centered psychotherapy; TNM, tumor, node, metastasis.
Data are presented as a mean±standard deviation or number (%).
1110
Meaning-Centered Psychotherapy for Cancer
https://doi.org/10.3349/ymj.2018.59.9.1107
years of education in the MCP group was 9.39 (±4.52) years. 
The number of patients with tumor, node, metastasis (TNM) 
stages I and II was higher than the number of patients with 
TNM stages III and IV for both groups. The time from the can-
cer diagnosis to the initial assessment was 30.36 (±68.53) days 
in the MCP group and 53.36 (±69.91) days in the non-MCP 
group, which were not significantly different (p=0.374). Among 
the patients, two in the non-MCP group were receiving psychi-
atric medication, SSRI and mood stabilizer with antipsychotics, 
respectively.
In the initial assessment, the patients in the MCP group 
showed significantly higher levels of distress (DS-DT, p<0.001), 
anxiety (HAD-A, p<0.001), and depression (HAD-D, p<0.001) 
than those in the non-MCP group. The scores of helpless-hope-
less (MAC-HH, p=0.001) and anxious preoccupation (MAC-
AP, p<0.001) items of the MAC scale were also significantly 
higher in the MCP group than in the non-MCP group. More-
over, the patients in the MCP group, in general, scored lower 
on the social and emotional functional scales of the QLQ-C30, 
and the overall QoL scale scores were significantly different 
between the two groups (p<0.001) (Table 3).
Effectiveness of MCP
Of the 24 patients who received MCP, 16 completed the ques-
tionnaire during the follow-up 2 months after the completion 
of MCP. Thirteen patients in the non-MCP group completed 
the questionnaire again 2 months after the initial assessment 
(Table 4). The patients in the MCP group showed significant 
improvements in the HADS-A (p=0.014), HADS-D (p=0.014), 
and MAC-AP (p=0.002) scores at the final assessment. In ad-
dition, cognitive function (QLQ-C30-CF, p=0.037), social func-
tion (QLQ-C30-SF, p=0.043), and global QoL (QLQ-C30-QoL, 
p=0.021) for patients in the MCP group were also significantly 
improved at the final assessment. Although there were no 
clinically significant changes in the scores between the initial 
and final assessments for the non-MCP group, a trend of in-
creasing distress was observed, based on the MAC-AP (p=0.031) 
and emotional function (QLQ-C30-EF, p=0.010) scores.
Changes in HADS-A (p=0.007) and HADS-D (p=0.010) scores 
between the initial and final assessments were significantly 
different between the MCP and non-MCP groups. Changes in 
MAC-AP score were also significantly different between the 
two groups (p<0.001). Moreover, the two groups showed sig-
nificantly different changes in the scores for EF (p=0.009), SF 
(p=0.022), and global QoL (p=0.017) subscales of the QLQ-
C30 (Fig. 1).
As the patients who received MCP scored significantly high-
er on several items assessing emotional distress and lower 
QoL at the initial assessment, the effects of these differences 
in the initial assessment were considered to affect the analysis 
of the therapeutic effect of MCP. In order to control for this, AN-
COVA was conducted with initial assessment scores of each 
scale showing a difference at baseline (e.g., HADS-A, HADS-D, 
HH, AP, RF, EF, SF, QoL, Pain, Jaundice) as the covariate of 
each scale to analyze changes in scores between the initial 
and follow-up assessments of the two groups (Table 5). FS, FA 
of MAC and all items of QLQ-C30 suggest improvement when 
showing positive changes, whereas HADS-A, HADS-D, HH, 
AP, CA of MAC, and all items of QLQ-PAN26 reflect improve-
ment when showing negative changes. This analysis showed 
that change in the anxious preoccupation (MAC-AP, p=0.041) 
Table 3. Comparison of Baseline Emotional Distress and QoL between 
MCP and Control Groups
Variable MCP (n=24) Non-MCP (n=13) p value
DS-DT 6.09±2.52 2.46±2.47 <0.001
HADS-A 8.71±4.58 2.23±1.92 <0.001
HADS-D 9.33±3.69 4.23±2.35 <0.001
MAC
HH 15.71±4.23 11.23±2.65 0.001
FS 12.04±1.97 11.23±2.08 0.249
AP 22.83±5.07 15.23±3.49 <0.001
FA 15.00±2.02 13.46±2.82 0.063
CA 10.63±2.37 10.62±2.57 0.991
QLQ-C30
PF 72.22±17.83 78.46±20.39 0.340
RF 56.94±36.09 83.33±20.41 0.026
EF 63.89±20.88 91.03±12.48 <0.001
CF 72.92±21.88 83.33±11.79 0.194
SF 54.86±30.88 88.46±15.79 0.001
QoL 34.72±25.14 67.95±19.79 <0.001
QLQ-PAN26
Pain 43.06±29.66 12.82±13.87 0.002
Digestive 40.28±30.66 21.79±24.89 0.071
Bowel 35.42±30.42 16.67±18.00 0.050
Jaundice 27.08±21.32 12.94±11.54 0.042
Body 43.06±35.75 34.62±24.96 0.455
Satisfaction 55.56±27.66 57.69±32.36 0.834
Sexual 21.74±31.15 33.33±29.30 0.294
SRRS
6m 73.00±84.36 27.92±30.34 0.159
7–12m 39.96±53.94 12.15±32.43 0.189
Sum 104.45±101.96 40.38±38.19 0.067
MCP, meaning-centered psychotherapy; DS-DT, National Comprehensive 
Cancer Network distress thermometer; HADS-A, Hospital Anxiety and De-
pression Scale, Anxiety subscale; HADS-D, HADS, Depression subscale; 
MAC, Mini-Mental Adjustment to Cancer Scale; HH, helpless-hopeless; FS, 
fighting spirit; AP, anxious preoccupation; FA, fatality; CA, cognitive avoid-
ance; QLQ-C30, European Organization for Research and Treatment of Cancer 
quality of life questionnaire core 30; PF, physical function; RF, role function; EF, 
emotional function; CF, cognitive function; SF, social function; QoL, global quali-
ty of life; QLQ-PAN26, European Organization for Research and Treatment of 
Cancer quality of life questionnaire pancreatic cancer-specific module; Pain, 
pancreatic pain; Bowel, altered bowel habit; Body, body image; Satisfaction, 
satisfaction with health care; Sexual, sexual functioning; SRRS, Social Readjust-
ment Rating Scale; 6m, within 6 months life change unit; 7–12m, 7–12 months 
life change unit; Sum, life change unit summation.
Data are presented as a mean±standard deviation.
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subscale of MAC alone was significantly different between the 
MCP and non-MCP groups. In other words, the anxious preoc-
cupation tendency in the MCP group showed significant posi-
tive changes, compared with the non-MCP group, when the dif-
ferences at the initial assessment were controlled. 
DISCUSSION
Patients with cancer experience a number of psychiatric symp-
toms, including depression, anxiety, and insomnia, in addition 
to physical symptoms.21 Pancreatobiliary cancer is one of the 
malignancies with the worst prognosis, so there is an even great-
Fig. 1. Comparison of changes from baseline to 2 months after MCP. The MCP and non-MCP groups showed significantly different changes between the 
initial and final assessments in the scores of (A) HADS-A (p=0.007) and (B) QLQ-C30-QoL (p=0.017). MCP, meaning-centered psychotherapy; HADS-A, 
Hospital Anxiety and Depression Scale, Anxiety subscale; QLQ-C30-QoL, European Organization for Research and Treatment of Cancer quality of life 
questionnaire core 30, global quality of life subscale; f/u, follow-up.
Table 4. Changes in Scores for Psychological Assessment of MCP and Control Groups
Variable
MCP (n=16) Non-MCP (n=13)
p value*
Baseline 2 mo f/u t p value Baseline 2 mo f/u t p value
HADS-A 8.00±4.70 5.06±4.14 2.785 0.014 2.23±1.92 3.69±2.06 -1.977 0.071 0.007
HADS-D 8.44±3.33 5.69±3.24 2.779 0.014 4.23±2.35 5.62±4.29 -1.251 0.235 0.010
MAC
HH 14.81±4.25 13.56±4.40 0.852 0.408 11.23±2.65 13.38±4.66 -1.689 0.117 0.099
FS 12.19±2.26 11.44±2.19 1.205 0.247 11.23±2.09 11.08±2.63 0.221 0.829 0.528
AP 22.25±5.65 17.94±5.08 3.692 0.002 15.23±3.49 18.62±4.72 -2.436 0.031 <0.001
FA 14.63±2.09 13.81±3.53 1.019 0.324 13.46±2.82 13.46±3.12 0.001 1.000 0.440
CA 10.38±2.68 10.38±3.46 0.001 1.000 10.61±2.57 11.15±2.54 -0.656 0.524 0.671
QLQ-C30
PF 74.38±18.83 69.17±27.64 1.140 0.272 78.46±20.39 68.72±23.79 1.456 0.169 0.568
RF 54.17±38.25 66.67±33.88 -1.307 0.211 83.33±20.41 74.36±25.11 1.534 0.151 0.082
EF 70.31±22.35 76.04±19.21 -1.102 0.288 91.03±12.48 76.28±21.20 3.055 0.010 0.009
CF 78.13±20.83 86.46±15.18 -2.739 0.037 83.33±11.79 83.33±18.00 0.001 0.713 0.131
SF 62.50±30.12 83.33±28.54 -2.207 0.043 88.46±15.79 79.49±23.72 1.289 0.222 0.022
QoL 35.42±26.61 52.60±24.29 -2.567 0.021 67.95±19.79 63.46±25.81 0.959 0.357 0.017
QLQ-PAN26
Pain 40.10±28.42 27.08±24.63 1.756 0.099 12.82±13.87 17.95±27.18 -0.780 0.450 0.085
Digestive 46.88±33.45 44.79±32.04 0.246 0.809 21.79±24.89 23.08±30.84 -0.113 0.912 0.811
Bowel 28.13±24.13 19.79±20.38 0.984 0.341 16.67±18.00 21.79±22.86 -0.574 0.576 0.286
Jaundice 26.04±23.55 18.75±20.97 0.861 0.403 7.69±12.94 11.54±18.49 -0.492 0.632 0.352
Body 40.63±38.47 31.25±29.11 0.855 0.406 34.62±24.96 20.51±20.59 1.442 0.175 0.756
Satisfaction 57.29±31.60 60.42±33.82 -0.299 0.769 57.69±32.36 55.13±29.17 0.253 0.805 0.703
Sexual 22.92±34.36 7.29±14.87 1.678 0.112 33.33±29.30 26.39±37.24 0.519 0.614 0.587
MCP, meaning-centered psychotherapy; HADS-A, Hospital Anxiety and Depression Scale, Anxiety subscale; HADS-D, HADS, Depression subscale; MAC, Mini-Mental 
Adjustment to Cancer Scale; HH, helpless-hopeless; FS, fighting spirit; AP, anxious preoccupation; FA, fatality; CA, cognitive avoidance; QLQ-C30, European Organiza-
tion for Research and Treatment of Cancer quality of life questionnaire core 30; PF, physical function; RF, role function; EF, emotional function; CF, cognitive function; SF, 
social function; QoL, global quality of life; QLQ-PAN26, European Organization for Research and Treatment of Cancer quality of life questionnaire pancreatic cancer-spe-
cific module; Pain, pancreatic pain; Bowel, altered bowel habit; Body, body image; Satisfaction, satisfaction with health care; Sexual, sexual functioning.
Data are presented as a mean±standard deviation.
*p value from independent T-test comparing the differences of initial assessment and 2 months later between the MCP and non-MCP group.
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er need for a psychiatric approach for these patients.3 One of 
the psychotherapeutic intervention that helps patients cope 
with the distress is MCP. There have been no reports of MCP 
being conducted in patients with advanced cancer in Korea. 
Thus, the present study aimed to evaluate the effectiveness and 
applicability of MCP in patients with pancreatobiliary cancer.
We examined emotional distress and QoL before MCP and 2 
months after its completion. The MCP group showed significant 
improvements in depression, anxiety, and anxious preoccupa-
tion related to mental adjustment to cancer, global QoL, cog-
nitive function, and social function, although the group had 
scored relatively poorly for emotional distress and QoL at the 
initial assessment. In contrast, no clinically significant changes 
in emotional distress and QoL were found between the initial 
and follow-up assessments in the non-MCP group. Although 
not statistically significant, a trend of increasing distress, based 
on the MAC-AP and QLQ-C30-EF scores, was observed in the 
non-MCP group. These results suggest that patients with ad-
vanced cancer, who experience clinically significant emotional 
distress and decreasing QoL, need an appropriate psychoso-
cial intervention. In addition, the MCP group showed signifi-
cantly higher scores in the initial assessment of QLQ-PAN26 
pain, jaundice. Higher anxiety and distress scores in the MCP 
group may be induced by severe physical symptoms. In addi-
tion, although not statistically significant, it is possible that 
MCP was assessed in severe physical symptoms because the 
time from cancer diagnosis to initial assessment was shorter 
than non-MCP. The important finding is that QLQ-PAN26, an 
evaluation item related to physical symptoms, did not show 
any significant improvement in any, while there was improve-
ment in EF score. The results suggest that the therapeutic effects 
of MCP may primarily involve relieving psychological symp-
toms, which can change the cognitive approach process and 
improve emotional state even if actual physical symptoms are 
similar. 
MCP is a psychotherapeutic intervention that helps patients 
cope with distress by enhancing meaning of life and spiritual 
well-being. So far, few psychological interventions have been 
developed, with psychological care more often being focused 
on providing psychoeducational or supportive interventions.13 
These interventions have rarely considered meaning of life and 
spiritual well-being an important issue. MCP is based on the 
writings of Viktor Frankl, a psychiatrist and holocaust survivor, 
and he suggested that people desire to find meaning in their 
existence even as they approach the end of life.11,22,23 This dif-
ference in the perspective of psychological care for cancer pa-
tients may cause MCP to be effective in patients with advanced 
cancer experiencing anxiety and pain related to the issue of 
“impending death.”12,13
The result of ANCOVA for assessing MCP effectiveness 
showed that only MAC-AP was significantly improved in pa-
tients after receiving MCP. MAC-AP is characterized by con-
stant preoccupation with cancer and feelings of anxiety, fear, 
and devastation.24 Previous studies have shown that a higher 
score on AP domain was associated with both anxiety and de-
pression, and has a negative impact on well-being, irrespective 
of phase of illness.25,26 In this study, we attempted not only to 
get a meaning of life from different perspectives through MCP, 
but also to understand the causes of anxiety and to learn how 
to control anxiety effectively through stress management. These 
attempts seem to have worked together to improve cancer-re-
lated anxiety. Other variables, except MAC-AP, did not show a 
significant difference in ANCOVA. This may be attributed to 
the fact that only the patients who reported clinically signifi-
cant distress in the initial assessment were selected for the 
MCP group. 
Table 5. Results for Changes in Scores for Psychological Assessment in 
MCP and Control Groups by ANCOVA
Variable MCP (n=16) Non-MCP (n=13) F p value
HADS-A -1.492 (0.851) -0.318 (0.968) 0.670 0.420
HADS-D -1.614 (1.011) -0.014 (1.147) 0.904 0.351
MAC
HH 0.050 (1.202) 0.554 (1.349) 0.070 0.794
FS -0.513 (0.564) -0.446 (0.627) 0.006 0.939
AP -2.803 (1.208) 1.527 (1.372) 4.610 0.041
FA -0.706 (0.706) -0.131 (0.785) 0.288 0.596
CA -0.068 (0.746) 0.622 (0.828) 0.382 0.542
QLQ-C30
PF -5.561 (5.278) -9.309 (5.859) 0.225 0.639
RF 5.356 (7.138) -0.182 (8.003) 0.242 0.627
EF 1.489 (4.746) -9.525 (5.343) 2.085 0.161
CF 7.421 (3.235) 1.123 (3.593) 1.678 0.207
SF 11.517 (7.055) 2.492 (7.930) 0.642 0.430
QoL 11.163 (5.828) 2.928 (6.600) 0.731 0.400
QLQ-PAN26
Pain -6.072 (6.543) -3.425 (7.377) 0.062 0.805
Digestive 5.998 (8.052) -8.664 (9.012) 1.358 0.255
Bowel -2.285 (5.496) -2.315 (6.120) <0.001 0.997
Jaundice 3.209 (5.130) -9.077 (5.754) 2.302 0.141
Body -6.849 (6.532) -17.212 (7.250) 1.123 0.299
Satisfaction 2.987 (7.893) -2.394 (8.756) 0.208 0.652
Sexual -19.981 (6.851) -1.137 (7.926) 3.193 0.086
ANCOVA, analysis of covariance; MCP, meaning-centered psychotherapy; 
HADS-A, Hospital Anxiety and Depression Scale, Anxiety subscale; HADS-D, 
HADS, Depression subscale; MAC, Mini-Mental Adjustment to Cancer Scale; 
HH, helpless-hopeless; FS, fighting spirit; AP, anxious preoccupation; FA, fatal-
ity; CA, cognitive avoidance; QLQ-C30, European Organization for Research and 
Treatment of Cancer quality of life questionnaire core 30; PF, physical function; 
RF, role function; EF, emotional function; CF, cognitive function; SF, social function; 
QoL, global quality of life; QLQ-PAN26, European Organization for Research and 
Treatment of Cancer quality of life questionnaire pancreatic cancer-specific 
module; Pain, pancreatic pain; Bowel, altered bowel habit; Body, body image; 
Satisfaction, satisfaction with health care; Sexual, sexual functioning.
Data are presented as an estimated marginal mean (standard error of the 
mean). Score changes with negative values in the HADS-A, HADS-D, MAC-HH, 
AP, and CA and positive values in the MAC-FS, FA, and QLQ-C30 items repre-
sent improvement.
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Approximately 66% of the participants completed all ses-
sions of MCP, which is much higher than the completion rate 
of the grouped format of MCP reported by previous studies.13 
Generally, MCP is provided in a group format. In the present 
study, however, patients missed or were unable to complete 
their sessions due to difficulties of scheduling or illness-relat-
ed problems. This suggests the need for a more flexible and 
personalized therapy for patients with advanced cancer. In 
our study, MCP was provided individually, and in many cases, 
patients were able to receive MCP after their outpatient visit to 
the surgery department. It is expected that this form of thera-
py will have positive effects on treatment compliance in clini-
cal practice. A previous study on MCP, however, showed that 
patients who received the individual format of MCP no longer 
showed improvement 2 months after its completion, whereas 
patients who received the grouped format showed continued 
improvement when they were followed up after more than 2 
months.12 Our study demonstrated the effectiveness of MCP up 
to 2 months after its completion, and further investigation in a 
long-term follow-up study may provide a better understanding 
of the patterns of MCP effectiveness. 
This study has several limitations. Firstly, the subjects were 
limited to patients with pancreatobiliary cancer, and the results 
may not be generalizable to all patients with cancer. Moreover, 
the small sample size of the MCP group lowers the statistical 
power. As mentioned above, ANCOVA showed significant ther-
apeutic effect in terms of MAC-AP scores alone, whereas the t-
test showed otherwise. More statistically significant results 
may be expected when larger sample sizes of MCP and con-
trol groups with clinically significant emotional distress are 
compared to assess therapeutic effects. In addition, although 
the patients of this study were recruited from three hospitals, 
the number of patients that the psychologists at each hospital 
were assigned to was not equal because different numbers of 
patients were recruited at each hospital. The therapist may in-
fluence the therapeutic effect and patient satisfaction. To mini-
mize the effect related with differences between therapists, 
we initiated this study after each therapist had had sufficient 
time to discuss the MCP program during the study preparation 
step. The MCP group was reassessed two months after the 
completion of the MCP, while the non-MCP group was reas-
sessed two months after the baseline. Therefore, there is a dif-
ference in the evaluation interval for each group, and these fac-
tors may have affected the outcome. Lastly, the MCP was only 
recommended to the patients who showed clinically significant 
levels of depression, anxiety, and distress in this study, and the 
results of the current study do not provide evidence for the ef-
fectiveness of MCP in patients without clinically significant 
psychiatric symptoms. 
Despite these limitations, our study showed that MCP helps 
patients with advanced cancer regain their sense of meaning in 
life and may reduce emotional distress, including depression 
and anxiety, and increase QoL. Our study is the first to attempt 
MCP intervention in patients with pancreatobiliary cancer in 
Korea. The need to treat the psychiatric symptoms of patients 
with cancer is clear, and further studies and clinical trials may 
establish MCP as an important therapeutic tool for treating pa-
tients with advanced cancer.
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